Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIST-rNB-2011: Multimodal Therapy in Relapsed Neuroblastoma
NCT01467986Phase 2Completed
- Sponsor
- University of Regensburg
- Start
- Aug 2013
- Primary completion
- Sep 2020
- Modality
- Fragment-Derived Small Molecules, Nanoparticles, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of nab-sirolimus, dasatinib in neuroblastoma, sponsored by University of Regensburg. Started Aug 2013; status: completed.
02
Drugs
nab-sirolimusdasatinib
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT01467986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01467986.